IPP Bureau
Novartis reports data from trial of IgA nephropathy treatment
By IPP Bureau - April 16, 2024
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
Suven Life Sciences to present phase-2 results on Samelisant at AAN 2024
By IPP Bureau - April 16, 2024
Global Phase-3 study initiation expected in the second half of 2024
Laurus Labs forms JV company
By IPP Bureau - April 16, 2024
KRKA holds 51% and Laurus Labs holds 49% shareholding
Croda and AAHI partner to drive innovation in vaccine development
By IPP Bureau - April 15, 2024
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
Teva confirms efficacy and safety of Ajovy for prevention of migraine
By IPP Bureau - April 15, 2024
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
Novartis tender offer for MorphoSys commences
By IPP Bureau - April 15, 2024
The offer price corresponds to a premium of 142% on the volume-weighted average price during the last three months
.jpg "Granules India’s Unit V facility in Visakhapatnam completes USFDA inspection with zero 483 observations")
Granules India’s Unit V facility in Visakhapatnam completes USFDA inspection with zero 483 observations
By IPP Bureau - April 14, 2024
This facility manufactures APIs & formulations of oncology and non-oncology products.
Briefs: Sun Pharma and Kimia Biosciences
By IPP Bureau - April 14, 2024
Sun Pharma's Dadra facility receives OAI status from US FDA
Merck India appoints Dhananjay Singh as MD Merck Life Science in India
By IPP Bureau - April 13, 2024
USFDA completes inspection of Lupin's Dabhasa facility with no observations
By IPP Bureau - April 13, 2024
The inspection was conducted from April 8 to April 12, 2024 and concluded with no observations
CRISPR-based innovations drive $21 billion in pharmaceutical licensing deals over five years, reveals GlobalData
By IPP Bureau - April 12, 2024
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
Generics gain ground, yet HCPs still favor branded drugs, finds GlobalData
By IPP Bureau - April 12, 2024
A significant proportion of healthcare professionals still tend to favor branded drugs
Pfizer announces positive results from Phase 3 Study of Abrysvo
By IPP Bureau - April 12, 2024
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
Cupid to supply Rs. 23.07 crore female condoms in Brazil
By IPP Bureau - April 12, 2024
Total value of the supplies of FC will be US$ 2.773 million
